Ascendis Pharma A/S

public$ASND View Live Feed →

Total Raised

Contracts

Patents

PAC Giving

Government Contracts & Awards

No recent government contracts or awards found.

Proprietary Tech & Patents

No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).

Form D Funding

No recent SEC Form D filings found.

Market Intelligence & News

Yahoo Sep 17, 2026

Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

Congressional Trades in $ASND

No disclosed congressional trades found in $ASND.

Insider Trades (Form 4)

SELLDirector

BIENAIME JEAN JACQUES

18,320 shares Sep 28, 2026

BUYDirector

BIENAIME JEAN JACQUES

$492,6542,000 shares Aug 19, 2026

Key People

BIENAIME JEAN JACQUES

Director

BoardInsider

Political Giving

No disclosed PAC contributions found for this entity.

Factual Connections

Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.

Upgrade to Pro